Related posts
This Week’s Stock Picks & BNN Top Picks Summary: IBKR-Q, TOI-X and 21 Stock and 3 ETF Top Picks (Apr 05-11)Consumer, housing data misses, stocks sinkWall Street edges up, Tesla beatsThis summary was created by AI, based on 21 opinions in the last 12 months.
Stryker Corp. (SYK-N) is a highly regarded medical devices company with a strong focus on key areas such as artificial joints and specialized medical equipment. The company benefits from a significant backlog of surgeries due to Covid, and its innovative products and relationships with surgeons position it well for future growth, both domestically and internationally. Experts agree that Stryker has a great story, with a strong brand loyalty and a demographic tailwind supporting its compounding growth for the next several years. The company's strong fundamentals and solid growth, coupled with the potential for further acquisitions, make it a compelling choice for long-term healthcare investors.
Revenue: US (73%), developed world (19%), emerging markets (rest). Lots of good growth internationally. Demographic play. Strong brand loyalty. Free cash will be used for acquisitions. Great compounding story for the next several years. Yield is 0.9%.
(Analysts’ price target is $356.78)AI and weight-loss drugs are the two manias in the market now. SYK makes medical devices (hip and knee), but you must be below a certain weight to qualify for these operations. The weight-loss drugs will open a greater market for SYK.
Great story. Medical devices is a really important area of healthcare. Tremendous brand loyalty from end-user, plus a demographic play. Great operating margins and quarterly numbers, which will just keep on getting better. Lots of growth internationally. Yield is 0.9%.
(Analysts’ price target is $350.67)Medical devices are an important area that keeps people out of expensive hospitals, improves quality of life, and reduces reliance on drugs. Great advances, which will grow over the years. You want to be in this area. He owns SYK and JNJ in the space.
Medical devices. Joint replacements. Huge backlog due to Covid. Costs increased from supply chains and labour, but now sorted out. Really improves quality of life. Great business, lots of growth from aging demographics. Lots of growth internationally, too. Once a doctor "buys in", tremendous brand loyalty. Yield is 1%.
(Analysts’ price target is $318.71)It is in the medical devices field producing parts for artificial knees, hips, etc. and improving patient quality of life. Surgeons tend to stick with the same products so there is a stability to its income. The backlog from Covid is being decreased but there is room to grow internationally and an aging population needs more of these surgeries. 72% of its business comes from the U.S. and the rest from emerging markets and the developed world. They have lots of free cash flow to buy other companies. Buy 18 Hold 11 Sell 1
(Analysts’ price target is $314.49)Doing well given the backlog in surgeries. 73% of their business is in the US, but there's growth in emerging markets where they also operate. Doctors stick with their products and seldom change. Also, aging demographics help. They could make acquisitions, which will benefit them.
(Analysts’ price target is $311.03)SYK has performed well this year, increasing as much as 24% year-to-date and as high as 48% (before the recent sell-off) on a one-year basis. Its valuation reached its historical high point of ~5.5X forward sales and ~28X forward earnings. Its fundamentals are strong and it continues to expand on most metrics, but we feel that its valuation became too stretched and we're beginning to see its price decline alongside the broader US healthcare market. We would be comfortable continuing to hold this name as part of a long-term healthcare position.
Unlock Premium - Try 5i Free
Stryker makes replacement body parts with several components involved. There is a huge backlog of elective surgeries due to Covid. Also an aging population needs more of these artificial parts so there is lots of growth ahead. Surgeons tend to use the same parts rather than switching to other makes. It has a great balance sheet and may make more acquisitions to grow the business. There may be some cost issues to deal with but this shouldn't be a problem. 70% of its business comes from the U.S. Buy 17 Hold 12 Sell 1
Great business with aging population.
Bullish on healthcare sector.
Good time to buy for long term investor.
Strong fundamentals.
They just reported a good quarter. They have solid growth; there will be more surgeries through the backlog.
Beneficiaries of increase in procedures since Covid. Replacement parts plus equipment. Never a cheap stock, but going into a growth period. Wouldn't hesitate to recommend it as part of a portfolio. Quality, well managed.
The caller was wondering whether to sell Johnson and Johnson and buy Stryker. Both are good companies and good for recessionary times. Johnson and Johnson is a consumer staple which sometimes has trouble with margins. He owns Stryker, a well run company.
Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N
In the last year, 8 stock analysts published opinions about SYK-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..
Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
8 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.
On 2024-04-17, Stryker Corp. (SYK-N) stock closed at a price of $336.03.
Demographic tailwind. User loyalty. Most revenue comes from US. Global growth opportunities, especially in EM. Medical devices are really changing how people live. Covid backlog is being caught up. Tuck-on acquisitions. Yield is 0.9%.
(Analysts’ price target is $360.04)